Marisa Wexler, MS,  senior science writer—

Bridge Biotherapeutics has entered into an exclusive option-to-license agreement with Cellion BioMed to develop BBT-301, an experimental ion modulator therapy, as a potential treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. “We are highly excited to in-license BBT-301, a novel drug candidate for the treatment of fibrotic…

The China National Intellectual Property Administration has granted AdAlta a patent covering AD-214, the biotech company’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The patent — number CN 107427574 B — entitled “CXCR4 binding molecules,” will expire in early January 2036. “China is now the second largest (and…

Boehringer Ingelheim Canada has finished negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) — a partnership between the country’s provincial, territorial and federal governments — for Ofev (nintedanib), the company’s approved oral medication for progressive fibrosing interstitial lung diseases (PF-ILD). The pCPA conducts negotiations with drug manufacturers for treatments…

A novel imaging biomarker identified via an artificial intelligence (AI)-powered analysis could help predict lung function and survival outcomes for people with idiopathic pulmonary fibrosis (IPF). Brainomix, a U.K.-based software company, is developing a number of AI-based tools to analyze different diseases, including one called e-ILD…

Patients with idiopathic pulmonary fibrosis (IPF) with chronic cough who are being treated with the investigational oral medication NP-120 (ifenprodil) in a small clinical trial tended to experience a reduction in coughing, according to the therapy’s developer Algernon Pharmaceuticals. The company is funding an open-label Phase 2…

Cudetaxestat (BLD-0409), an experimental medication for idiopathic pulmonary fibrosis (IPF) from Blade Therapeutics, was well-tolerated among healthy volunteers when given in combination with other IPF treatments — specifically nintedanib and pirfenidone — in a Phase 1 study. “These findings provide confidence in the potential to safely co-administer cudetaxestat…

Enrollment has been completed for INTEGRIS-IPF, a Phase 2a trial testing PLN-74809, an experimental oral anti-fibrotic therapy, in people with idiopathic pulmonary fibrosis (IPF). Pliant Therapeutics, the company developing PLN-74809 and sponsoring the trial, said it is expecting top-line results to become available midway through the year. The…

Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…

Some people with so-called “long COVID” — breathlessness and other respiratory symptoms that persist long after the acute phase of COVID-19 infection — may have had undiagnosed pulmonary fibrosis before they contracted the infection. Scientists at University of Michigan Health reported these findings in the study, “…

Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Under the agreement, Chiesi acquired global exclusive rights to develop and manufacture the potential antifibrotic therapy, and to market it should it be approved.